{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:00:44Z","timestamp":1762326044582,"version":"3.44.0"},"reference-count":28,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,11,5]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>A patient with a long history of bone predominant, metastatic paraganglioma who had multiple episodes of progressive disease despite prior treatments demonstrated a remarkable disease response to zoledronic acid. After 1 year of treatment, there was a complete resolution of lymphadenopathy and disappearance of all somatostatin receptor avid lesions by positron emission tomography-CT and radiopharmaceutical Gallium Ga 68 Dotatate. Stability of disease was further demonstrated by CT over several years. The patient continues on surveillance.<\/jats:p>","DOI":"10.1136\/bcr-2024-262628","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:02:18Z","timestamp":1732845738000},"page":"e262628","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7567-6991","authenticated-orcid":false,"given":"Justin","family":"Schutte","sequence":"first","affiliation":[{"name":"Internal Medicine \u2013 Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahta","family":"Mardani","sequence":"additional","affiliation":[{"name":"Internal Medicine \u2013 Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Weilbaecher","sequence":"additional","affiliation":[{"name":"Internal Medicine \u2013 Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[{"name":"Radiology \u2013 Nuclear Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S A","family":"Chrisinger","sequence":"additional","affiliation":[{"name":"Pathology \u2013 Anatomic and Molecular Pathology (AMP), Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos A","family":"Trikalinos","sequence":"additional","affiliation":[{"name":"Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2025082712130980000_17.11.e262628.1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"Eur J Intern Med"},{"key":"2025082712130980000_17.11.e262628.2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e13099","article-title":"Incidence of bone metastases in U.S. patients with solid tumors","volume":"34","author":"Hernandez","year":"2016","journal-title":"JCO"},{"key":"2025082712130980000_17.11.e262628.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069908","article-title":"Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study","volume":"13","author":"Zhang","year":"2023","journal-title":"BMJ Open"},{"key":"2025082712130980000_17.11.e262628.4","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S28339"},{"key":"2025082712130980000_17.11.e262628.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"2025082712130980000_17.11.e262628.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1721-x"},{"key":"2025082712130980000_17.11.e262628.7","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082712130980000_17.11.e262628.8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2025082712130980000_17.11.e262628.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651"},{"key":"2025082712130980000_17.11.e262628.10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025082712130980000_17.11.e262628.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23812"},{"key":"2025082712130980000_17.11.e262628.12","unstructured":"Drug approval package: zometa (zoledronic acid) nda #21-386. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-386_Zometa.cfm [Accessed 11 Apr 2024]."},{"key":"2025082712130980000_17.11.e262628.13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00774-023-01434-x","article-title":"Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology","volume":"41","author":"Coleman","year":"2023","journal-title":"J Bone Miner Metab"},{"key":"2025082712130980000_17.11.e262628.14","first-page":"004","article-title":"Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"15","author":"D\u2019Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"key":"2025082712130980000_17.11.e262628.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.04.003"},{"key":"2025082712130980000_17.11.e262628.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3055"},{"key":"2025082712130980000_17.11.e262628.17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2010.10.002","article-title":"Implications of bone metastases and the benefits of bone-targeted therapy","volume":"37 Suppl 2","author":"Lipton","year":"2010","journal-title":"Semin Oncol"},{"key":"2025082712130980000_17.11.e262628.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70302-X"},{"key":"2025082712130980000_17.11.e262628.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105195"},{"key":"2025082712130980000_17.11.e262628.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-053014-103600","article-title":"Adjuvant Bisphosphonates and Breast Cancer Survival","volume":"67","author":"Strobl","year":"2016","journal-title":"Annu Rev Med"},{"key":"2025082712130980000_17.11.e262628.21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0206"},{"key":"2025082712130980000_17.11.e262628.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70204-3"},{"key":"2025082712130980000_17.11.e262628.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02647"},{"key":"2025082712130980000_17.11.e262628.24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082712130980000_17.11.e262628.25","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab054","article-title":"MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice","volume":"5","author":"Paterson","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"2025082712130980000_17.11.e262628.26","doi-asserted-by":"crossref","unstructured":"Rogers MJ , M\u00f6nkk\u00f6nen J , Munoz MA . Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 2020;139. doi:10.1016\/j.bone.2020.115493","DOI":"10.1016\/j.bone.2020.115493"},{"key":"2025082712130980000_17.11.e262628.27","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-9-177","article-title":"Tumour macrophages as potential targets of bisphosphonates","volume":"9","author":"Rogers","year":"2011","journal-title":"J Transl Med"},{"key":"2025082712130980000_17.11.e262628.28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/ERC-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","volume":"29","author":"Wang","year":"2022","journal-title":"Endocr Relat Cancer"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-262628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:13:19Z","timestamp":1756321999000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-262628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,28]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bcr-2024-262628"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-262628","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}